Why Is HIMS Stock Down So Much? Should You Buy?
HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which previously allowed Hims & Hers to sell compounded alternatives. Compounded versions were permitted during the shortage but are now restricted unless they meet specific exceptions.
11hon MSN
The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.
The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Hims & Hers Health (HIMS) stock falls as the FDA declares that Novo Nordisk's (NVO) weight loss therapies are no longer in ...
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
UnitedHealth declines following a report that the Justice Department has been investigating the company’s Medicare billing ...
Shares of Hims & Hers Health (HIMS) are getting crushed today after the Food & Drug Administration determined there is no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback